Year: 2026
Type: article
Study design: Case Report
Abstract: Atomoxetine is one of the FDA-approved non-stimulant pharmacological agents used in the treatment of ADHD. It is commonly used in cases where patients are unresponsive to or unable to tolerate psychostimulants. The most frequently reported side effects include loss of appetite, abdominal pain, headache, and irritability. However, one of the rarely reported side effects in the literature is Raynaud’s phenomenon. In this case, we present a 7-year-old male who developed Raynaud’s phenomenon following the administration of atomoxetine.
Source: Türk tıp dergisi.
DOI: 10.70852/tmj.1847521
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7204462746